> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Brintellix
- URL: https://www.fdaweb.com/review-period-set-for-brintellix/
- Published: 2016-04-04T12:00:00.000Z
- Updated: 2026-09-14T20:52:41.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135261

*Federal Register* Notice: FDA has determined the regulatory review period for Brintellix (vortioxetine hydrobromide) is 2,343 days for extending a patent that claims the human drug product. Brintellix is indicated for treating major depressive disorder. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-04-04/pdf/2016-07477.pdf?ref=fdaweb.com)